© 2020 MJH Life Sciences and OncLive. All rights reserved.
December 05, 2019
Parminder Singh, MD, discusses potential implications of the phase III IMvigor130 trial in advanced bladder cancer.
October 29, 2019
Parminder Singh, MD, discusses the improvement in overall response rates with immunotherapy, targeted therapy, and antibody-drug conjugates in advanced urothelial cancer.
October 22, 2019
Parminder Singh, MD, discusses combination treatments that are being evaluated in localized bladder cancer.
September 04, 2019
Parminder Singh, MD, hematologist/oncologist, Mayo Clinic, discusses research being done with antibody-drug conjugates (ADCs) in advanced bladder cancer.